Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Glaxosmithkline Plc (GSK)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 108,906,008
  • Shares Outstanding, K 2,458,930
  • Annual Sales, $ 37,798 M
  • Annual Income, $ 1,236 M
  • 36-Month Beta 1.04
  • Price/Sales 2.87
  • Price/Cash Flow 11.05
  • Price/Book 15.67

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.14 +1.90%
on 06/12/17
44.53 -1.28%
on 05/31/17
+1.29 (+3.02%)
since 05/26/17
3-Month
40.45 +8.68%
on 04/27/17
44.53 -1.28%
on 05/31/17
+1.27 (+2.97%)
since 03/27/17
52-Week
37.20 +18.17%
on 12/08/16
45.58 -3.55%
on 08/02/16
+3.82 (+9.52%)
since 06/27/16

Most Recent Stories

More News
Global Vasculitis Treatment Market to Grow at a CAGR of 4.2% 2017-2021: Key Vendors are Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche & GlaxoSmithKline - Research and Markets

Research and Markets has announced the addition of the "Global Vasculitis Treatment Market 2017-2021" report to their offering.

CELGZ : 1.14 (unch)
GSK : 43.96 (-0.25%)
Global Vasculitis Treatment Market to Grow at a CAGR of 4.2% 2017-2021: Key Vendors are Bristol-Myers Squibb, Celgene, F. Hoffmann-La Roche & GlaxoSmithKline

Research and Markets has announced the addition of the "Global Vasculitis Treatment Market 2017-2021" report to their offering. The global vasculitis treatment market to grow at a CAGR of 4.20 % during...

ALDR : 15.40 (-17.65%)
ALPMF : 12.4900 (+1.20%)
ATRS : 3.10 (-1.59%)
ACOR : 19.30 (+0.52%)
CELGZ : 1.14 (unch)
GSK : 43.96 (-0.25%)
BMY : 56.44 (-0.84%)
TalenTeam appoints its first Learning Architect to complement the capabilities of its growing team of learning consultants

Euna has spent the last 11 years supporting customers of all sizes and across various industries with the SuccessFactors Learning solution - previously branded Plateau.

AHOND : 23.7500 (unch)
GSK : 43.96 (-0.25%)
Novartis Cardiovascular Drug Positive, NSCLC Drug Approved

Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug.

LLY : 83.59 (-0.82%)
NVS : 86.08 (+0.38%)
REGN : 517.19 (+0.25%)
GSK : 43.96 (-0.25%)
Today's Research Reports on Stocks to Watch: Geron Corporation and Teva Pharmaceutical

NEW YORK, NY / ACCESSWIRE / June 23, 2017 / It was a disappointing day for Teva Pharmaceutical Industries on Thursday, but judging by the gains the stock saw yesterday nobody would have known it. The...

GERN : 2.91 (-1.02%)
TEVA : 32.80 (-0.46%)
GSK : 43.96 (-0.25%)
Glaxo's (GSK) Shingles Candidate Phase III Data Positive

GlaxoSmithKline plc (GSK) announced positive top-line results from a phase III revaccination study on its shingles vaccine candidate, Shingrix, in older patients.

VVUS : 1.20 (+0.84%)
MRK : 65.90 (-0.03%)
TEVA : 32.80 (-0.46%)
GSK : 43.96 (-0.25%)
Novartis Announces Positive Results for Cardiovascular Drug

Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug.

VVUS : 1.20 (+0.84%)
NVS : 86.08 (+0.38%)
RHHBY : 32.6500 (+0.55%)
GSK : 43.96 (-0.25%)
North America Dietary Supplements Market 2014-2017 & 2025 By Ingredient (Botanicals, Vitamins, Minerals), Product (Tablets, Capsules, Gel Caps), By Application, By End-use

Research and Markets has announced the addition of the "North America Dietary Supplements Market Analysis By Ingredient (Botanicals, Vitamins, Minerals), By Product (Tablets, Capsules, Gel Caps), By Application,...

BAYRY : 137.3100 (+0.45%)
ABT : 48.95 (+0.08%)
HLF : 72.58 (-0.93%)
NATR : 13.50 (unch)
XOM : 81.36 (+0.15%)
GSK : 43.96 (-0.25%)
GSK presents positive results from Phase III revaccination study of its candidate shingles vaccine Shingrix at CDC's Advisory Meeting

GSK (LSE/NYSE: GSK) today will be presenting new results from a clinical study showing that its candidate vaccine for the prevention of herpes zoster (shingles) in people aged 50 years or older, Shingrix...

AGEN : 3.99 (-1.24%)
GSK : 43.96 (-0.25%)
Global Herpes Treatment Market to Grow at a CAGR of 12.9% by 2021 - Key Vendors are Gilead, GlaxoSmithKline, Merck & Novartis - Research and Markets

Research and Markets has announced the addition of the "Global Herpes Treatment Market 2017-2021" report to their offering.

MRK : 65.90 (-0.03%)
NVS : 86.08 (+0.38%)
GSK : 43.96 (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

GlaxoSmithKline is one of the world's leading research based pharmaceutical and healthcare companies and is committed to improving the quality of human life by enabling people to do more, feel better and live longer. They also have leadership in four major therapeutic areas: anti-infectives, central...

See More

Support & Resistance

2nd Resistance Point 44.58
1st Resistance Point 44.32
Last Price 43.96
1st Support Level 43.93
2nd Support Level 43.80

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.